<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01300065</url>
  </required_header>
  <id_info>
    <org_study_id>642</org_study_id>
    <nct_id>NCT01300065</nct_id>
  </id_info>
  <brief_title>Evaluation of Two Daily Disposable Contact Lenses.</brief_title>
  <official_title>A Study to Evaluate the Product Performance of Two Daily Disposable Contact Lenses</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bausch &amp; Lomb Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bausch &amp; Lomb Incorporated</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this clinical study is to evaluate the product performance of SofLens daily&#xD;
      disposable contact lenses packaged in the investigational Test solution versus SofLens daily&#xD;
      disposable contact lenses packaged in Control, solution as it relates to comfort when used by&#xD;
      subjects who use technology devices (eg, Personal Digital Assistants [PDAs], computers,&#xD;
      electronic game consoles, hand-held electronic devices, electronic book readers, etc) on an&#xD;
      average of 4 hours per day over a week's time for a minimum of 4 days each week.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Eyes With &gt; Grade 2 Slit Lamp Findings</measure>
    <time_frame>2 weeks</time_frame>
    <description>Graded slit lamp findings for each eye, including epithelial edema, epithelial microcysts, corneal staining, limbal and bulbar injections, upper lid tarsal conjunctival abnormalities, corneal neovascularization, and corneal infiltrates were graded for severity on a scale from 0 (No Finding) to 4 (Severe Finding). The outcome measure is any finding &gt; grade 2, across abnormalities.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Initial Lens Performance Survey</measure>
    <time_frame>At dispensing</time_frame>
    <description>A lens performance survey was given to each participant at the Screening/Dispensing Visit, three minutes following insertion of the study lenses. Lens performance was assessed by eye for the following parameters: burning/stinging upon insertion, comfort upon insertion, ease of handling/insertion, vision upon insertion, and lens cleanness upon insertion. As with symptoms/complaints, responses were on a scale from 0 to 100, with 0 being the most unfavorable score.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">441</enrollment>
  <condition>Myopia</condition>
  <arm_group>
    <arm_group_label>Experimental- Soflens</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bausch &amp; Lomb experimental soflens daily disposable contact lens packaged in an investigational storage solution.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Marketed - Soflens</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bausch &amp; Lomb daily disposable marketed soflens contact lens packaged with: 0.5% poloxamine in buffered saline solution.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Experimental- Soflens</intervention_name>
    <description>A new pair of lenses will be worn each day while the subject is in the study</description>
    <arm_group_label>Experimental- Soflens</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Marketed - Soflens</intervention_name>
    <description>A new pair of lenses will be worn each day while the subject is in the study.</description>
    <arm_group_label>Marketed - Soflens</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects must be correctable through spherocylindrical refraction to 32 letters (0.3&#xD;
             logMAR) or better (distance, high contrast) in each eye.&#xD;
&#xD;
          -  Subjects must be free of any anterior segment disorders.&#xD;
&#xD;
          -  Subjects must be adapted soft contact lens wearers and wear a lens in each eye and&#xD;
             each lens must be of the same manufacture and brand.&#xD;
&#xD;
          -  Subjects must be myopic and require contact lens correction from -0.50 D to -6.00 D in&#xD;
             each eye.&#xD;
&#xD;
          -  Subjects must be willing and able to wear the study lenses for at least 8 hours (12&#xD;
             hours or more is recommended) each day throughout the duration of the study.&#xD;
&#xD;
          -  Subjects must use a technologic device for an average of 4 hours per day over a week's&#xD;
             time and at a minimum of 4 days per week.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects who have worn gas permeable (GP) contact lenses within the last 30 days or&#xD;
             who have worn polymethylmethacrylate (PMMA) lenses within the last three months.&#xD;
&#xD;
          -  Subjects with any systemic disease currently affecting ocular health or which in the&#xD;
             Investigator's opinion may have an effect on ocular health during the course of the&#xD;
             study.&#xD;
&#xD;
          -  Subjects using any systemic or topical medications that will, in the Investigator's&#xD;
             opinion, affect ocular physiology or lens performance.&#xD;
&#xD;
          -  Subjects with an active ocular disease or who are using any ocular medication.&#xD;
&#xD;
          -  Subjects with corneal infiltrates, of ANY GRADE, are not eligible.&#xD;
&#xD;
          -  Subjects with any &quot;Present&quot; finding during the slit lamp examination that, in the&#xD;
             Investigator's judgment, interferes with contact lens wear.&#xD;
&#xD;
          -  Subjects with any scar or neovascularization within the central 4 mm of the cornea.&#xD;
&#xD;
          -  Subjects who have had any corneal surgery (eg, refractive surgery).&#xD;
&#xD;
          -  Subjects who are allergic to any component in the study care products.&#xD;
&#xD;
          -  Subjects may not use their habitual rewetting drops while participating in this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Beverly J Barna, CCRA</last_name>
    <role>Study Director</role>
    <affiliation>Bausch &amp; Lomb Incorporated</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bausch &amp; Lomb Incorporated</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>February 17, 2011</study_first_submitted>
  <study_first_submitted_qc>February 17, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 21, 2011</study_first_posted>
  <results_first_submitted>August 21, 2020</results_first_submitted>
  <results_first_submitted_qc>September 11, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 6, 2020</results_first_posted>
  <last_update_submitted>September 11, 2020</last_update_submitted>
  <last_update_submitted_qc>September 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>contact lens</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myopia</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>There were 441 participants (882 eyes) enrolled, 221 in the test group and 220 in the control group. There were 434 eligible participants (868 eyes) who participated in the study, 216 in the test group and 218 in the control group.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Experimental- Soflens</title>
          <description>Bausch &amp; Lomb experimental soflens daily disposable contact lens packaged in an investigational storage solution.&#xD;
Experimental- Soflens: A new pair of lenses will be worn each day while the subject is in the study</description>
        </group>
        <group group_id="P2">
          <title>Marketed - Soflens</title>
          <description>Bausch &amp; Lomb daily disposable marketed soflens contact lens packaged with: 0.5% poloxamine in buffered saline solution.&#xD;
Marketed - Soflens: A new pair of lenses will be worn each day while the subject is in the study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="221"/>
                <participants group_id="P2" count="220"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="215"/>
                <participants group_id="P2" count="217"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Eligible, dispensed participants were summarized.</population>
      <group_list>
        <group group_id="B1">
          <title>Experimental- Soflens</title>
          <description>Bausch &amp; Lomb experimental soflens daily disposable contact lens packaged in an investigational storage solution.&#xD;
Experimental- Soflens: A new pair of lenses will be worn each day while the subject is in the study</description>
        </group>
        <group group_id="B2">
          <title>Marketed - Soflens</title>
          <description>Bausch &amp; Lomb daily disposable marketed soflens contact lens packaged with: 0.5% poloxamine in buffered saline solution.&#xD;
Marketed - Soflens: A new pair of lenses will be worn each day while the subject is in the study.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="215"/>
            <count group_id="B2" value="216"/>
            <count group_id="B3" value="431"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.1" lower_limit="15" upper_limit="40"/>
                    <measurement group_id="B2" value="26.6" lower_limit="15" upper_limit="50"/>
                    <measurement group_id="B3" value="26.8" lower_limit="15" upper_limit="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="140"/>
                    <measurement group_id="B2" value="153"/>
                    <measurement group_id="B3" value="293"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Eyes With &gt; Grade 2 Slit Lamp Findings</title>
        <description>Graded slit lamp findings for each eye, including epithelial edema, epithelial microcysts, corneal staining, limbal and bulbar injections, upper lid tarsal conjunctival abnormalities, corneal neovascularization, and corneal infiltrates were graded for severity on a scale from 0 (No Finding) to 4 (Severe Finding). The outcome measure is any finding &gt; grade 2, across abnormalities.</description>
        <time_frame>2 weeks</time_frame>
        <population>There were 438 eyes in the test group and 434 eyes in the control group that were assessed for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental- Soflens</title>
            <description>Bausch &amp; Lomb experimental soflens daily disposable contact lens packaged in an investigational storage solution.&#xD;
Experimental- Soflens: A new pair of lenses will be worn each day while the subject is in the study</description>
          </group>
          <group group_id="O2">
            <title>Marketed - Soflens</title>
            <description>Bausch &amp; Lomb daily disposable marketed soflens contact lens packaged with: 0.5% poloxamine in buffered saline solution.&#xD;
Marketed - Soflens: A new pair of lenses will be worn each day while the subject is in the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Eyes With &gt; Grade 2 Slit Lamp Findings</title>
          <description>Graded slit lamp findings for each eye, including epithelial edema, epithelial microcysts, corneal staining, limbal and bulbar injections, upper lid tarsal conjunctival abnormalities, corneal neovascularization, and corneal infiltrates were graded for severity on a scale from 0 (No Finding) to 4 (Severe Finding). The outcome measure is any finding &gt; grade 2, across abnormalities.</description>
          <population>There were 438 eyes in the test group and 434 eyes in the control group that were assessed for this outcome measure.</population>
          <units>eyes</units>
          <param>Count of Units</param>
          <units_analyzed>eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="219"/>
                <count group_id="O2" value="217"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="438"/>
                <count group_id="O2" value="434"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Initial Lens Performance Survey</title>
        <description>A lens performance survey was given to each participant at the Screening/Dispensing Visit, three minutes following insertion of the study lenses. Lens performance was assessed by eye for the following parameters: burning/stinging upon insertion, comfort upon insertion, ease of handling/insertion, vision upon insertion, and lens cleanness upon insertion. As with symptoms/complaints, responses were on a scale from 0 to 100, with 0 being the most unfavorable score.</description>
        <time_frame>At dispensing</time_frame>
        <population>There were 426 eyes in the test group and 424 eyes in the control group that were assessed for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental- Soflens</title>
            <description>Bausch &amp; Lomb experimental soflens daily disposable contact lens packaged in an investigational storage solution.&#xD;
Experimental- Soflens: A new pair of lenses will be worn each day while the subject is in the study</description>
          </group>
          <group group_id="O2">
            <title>Marketed - Soflens</title>
            <description>Bausch &amp; Lomb daily disposable marketed soflens contact lens packaged with: 0.5% poloxamine in buffered saline solution.&#xD;
Marketed - Soflens: A new pair of lenses will be worn each day while the subject is in the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Initial Lens Performance Survey</title>
          <description>A lens performance survey was given to each participant at the Screening/Dispensing Visit, three minutes following insertion of the study lenses. Lens performance was assessed by eye for the following parameters: burning/stinging upon insertion, comfort upon insertion, ease of handling/insertion, vision upon insertion, and lens cleanness upon insertion. As with symptoms/complaints, responses were on a scale from 0 to 100, with 0 being the most unfavorable score.</description>
          <population>There were 426 eyes in the test group and 424 eyes in the control group that were assessed for this outcome measure.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="213"/>
                <count group_id="O2" value="212"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="426"/>
                <count group_id="O2" value="424"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Burning/stinging upon insertion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.6" spread="18.7"/>
                    <measurement group_id="O2" value="91.0" spread="18.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Comfort Upon Insertion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.8" spread="21.1"/>
                    <measurement group_id="O2" value="83.9" spread="21.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ease of Handling/Insertion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.2" spread="26.2"/>
                    <measurement group_id="O2" value="79.4" spread="26.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vision Upon Insertion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.3" spread="15.5"/>
                    <measurement group_id="O2" value="88.4" spread="15.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lens Cleanness Upon Insertion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.4" spread="10.8"/>
                    <measurement group_id="O2" value="94.9" spread="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 weeks</time_frame>
      <desc>Adverse events were not coded. Therefore, source vocabulary is not applicable.There were 440 eyes dispensed test lenses and 436 eyes dispensed control lenses, assessed for adverse events.</desc>
      <group_list>
        <group group_id="E1">
          <title>Experimental- Soflens</title>
          <description>Bausch &amp; Lomb experimental soflens daily disposable contact lens packaged in an investigational storage solution.&#xD;
Experimental- Soflens: A new pair of lenses will be worn each day while the subject is in the study</description>
        </group>
        <group group_id="E2">
          <title>Marketed - Soflens</title>
          <description>Bausch &amp; Lomb daily disposable marketed soflens contact lens packaged with: 0.5% poloxamine in buffered saline solution.&#xD;
Marketed - Soflens: A new pair of lenses will be worn each day while the subject is in the study.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Contact sponsor directly for details.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Bausch Health</organization>
      <phone>908-300-9920</phone>
      <email>susan.harris@bauschhealth.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

